CUAMC
JBIO

China Universal Asset Management Company’s Jade Biosciences JBIO Stock Holding History

China Universal Asset Management Company’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-7
Closed -$4K – 401
2022
Q3 		$4K Buy
+7
New +$4.67K ﹤0.01% 290

Other funds holding JBIO

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

China Universal Asset Management Company's JBIO Position: Q4 2022 in Review

China Universal Asset Management Company sold out of Jade Biosciences (JBIO) in Q4 2022, closing a stake of 7 shares — an estimated $4K sold.

China Universal Asset Management Company first reported a position in JBIO in Q3 2022 and held it in 1 quarter. The position peaked at $4K in Q3 2022. 68 funds tracked by Wall St. Rank hold JBIO as of Q4 2022.

  • China Universal Asset Management Company reported no remaining Jade Biosciences position as of Q4 2022 after selling out during the quarter.
  • China Universal Asset Management Company sold 7 Jade Biosciences shares in Q4 2022, an estimated $4K.
  • China Universal Asset Management Company first reported a position in Jade Biosciences in Q3 2022 and held it in 1 quarter.
  • China Universal Asset Management Company's Jade Biosciences position peaked at $4K in Q3 2022.
  • 68 funds tracked by Wall St. Rank held Jade Biosciences as of Q4 2022.

Based on China Universal Asset Management Company's 13F filing for Q4 2022, filed 31 Jan 2023.